source
- FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type AThe U.S. Food and Drug Administration today approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known…
- North Immunology to go public via reverse merger with Aethlon, targeting eczema marketNorth Immunology, an early-stage biotech developing a dual-acting antibody for eczema, announced plans to become a public company through a reverse merger with Aethlon Medical. The transaction wil…